Cargando…

Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts

PTEN inactivation occurs commonly in human cancers and putatively activates the PI3K/AKT/ mTOR pathway. Activation of this pathway has been involved in resistance to chemotherapy or anti-EGFR/HER2 therapies. We evaluated the combination of PI3K-mTOR inhibitors with chemotherapy or the pan-HER inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brana, Irene, Pham, Nhu-An, Kim, Lucia, Sakashita, Shingo, Li, Ming, Ng, Christine, Wang, Yuhui, Loparco, Peter, Sierra, Rafael, Wang, Lisa, Clarke, Blaise A., Neel, Benjamin G., Siu, Lillian L., Tsao, Ming-Sound
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Priority Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689564/ https://www.ncbi.nlm.nih.gov/pubmed/29156674 http://dx.doi.org/10.18632/oncotarget.19109

Ejemplares similares

Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302
por: Lohse, Ines, et al.
Publicado: (2016)

The nuclear import of ribosomal proteins is regulated by mTOR
por: Kazyken, Dubek, et al.
Publicado: (2014)

Point mutations of the mTOR-RHEB pathway in renal cell carcinoma
por: Ghosh, Arindam P., et al.
Publicado: (2015)

The NRF2 antagonist ML385 inhibits PI3K‐mTOR signaling and growth of lung squamous cell carcinoma cells
por: Ji, Lili, et al.
Publicado: (2022)

Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors
por: Vaughan, Lynsey, et al.
Publicado: (2016)

Regulation of mTOR complexes in long-lived growth hormone receptor knockout and Snell dwarf mice
por: Shi, Xiaofang, et al.
Publicado: (2022)

Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical model
por: Hasan, Md. Nabiul, et al.
Publicado: (2014)

Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts
por: Rosen, Joshua C., et al.
Publicado: (2021)

Retinoblastoma cells activate the AKT pathway and are vulnerable to the PI3K/mTOR inhibitor NVP-BEZ235
por: Xie, Chencheng, et al.
Publicado: (2017)

Overactive mTOR signaling leads to endometrial hyperplasia in aged women and mice
por: Bajwa, Preety, et al.
Publicado: (2016)

Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling
por: Brunen, Diede, et al.
Publicado: (2016)

Optimizing Drug Response Study Design in Patient-Derived Tumor Xenografts
por: Weiss, Jessica, et al.
Publicado: (2022)

Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in KRAS-mutant non-small cell lung cancer
por: Haines, Eric, et al.
Publicado: (2018)

CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition
por: Gopalan, Priya K., et al.
Publicado: (2018)

A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA(+) oral cancers
por: Yamaguchi, Kosuke, et al.
Publicado: (2016)

MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma
por: Lee, J. Scott, et al.
Publicado: (2015)

Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways
por: Jain, Payal, et al.
Publicado: (2017)

Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells
por: Litchfield, Lacey M., et al.
Publicado: (2020)

Inhibition of the AKT/mTOR pathway negatively regulates PTEN expression via miRNAs: Effect of Akt/mTOR inhibition on PTEN expression
por: Wan, Linyan, et al.
Publicado: (2022)

Patient-derived cell line, xenograft and organoid models in lung cancer therapy
por: Huo, Ku-Geng, et al.
Publicado: (2020)

The ISG15-specific protease USP18 regulates stability of PTEN
por: Mustachio, Lisa Maria, et al.
Publicado: (2016)

Comparison of SARS-CoV-2 RT-PCR on a high-throughput molecular diagnostic platform and the cobas SARS-CoV-2 test for the diagnostic of COVID-19 on various clinical samples
por: Opota, Onya, et al.
Publicado: (2020)

PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity
por: Noguera, Nélida Inés, et al.
Publicado: (2016)

Assessment of Hypoxia in the Stroma of Patient-Derived Pancreatic Tumor Xenografts
por: Lohse, Ines, et al.
Publicado: (2014)

A novel peptide that inhibits E2F transcription and regresses prostate tumor xenografts
por: Xie, Xiaoqi, et al.
Publicado: (2014)

Inhibition of porcupine prolongs metastasis free survival in a mouse xenograft model of Ewing sarcoma
por: Hayashi, Masanori, et al.
Publicado: (2017)

Synthetic lethality of a cell-penetrating anti-RAD51 antibody in PTEN-deficient melanoma and glioma cells
por: Turchick, Audrey, et al.
Publicado: (2019)

Prognostic Significance of mTOR and PTEN in Patients with Esophageal Squamous Cell Carcinoma
por: Lu, Jianjun, et al.
Publicado: (2015)

Pharmacological inhibition of p38 MAPK reduces tumor growth in patient-derived xenografts from colon tumors
por: Gupta, Jalaj, et al.
Publicado: (2015)

MAF1 suppresses AKT‐mTOR signaling and liver cancer through activation of PTEN transcription
por: Li, Yue, et al.
Publicado: (2016)

The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib
por: Piscitelli, Joseph, et al.
Publicado: (2022)

Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts
por: Wei, Lei, et al.
Publicado: (2016)

Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity
por: Takizawa, Itsuhiro, et al.
Publicado: (2014)

Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones
por: Carrà, Giovanna, et al.
Publicado: (2017)

ASXL1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts
por: Valletta, Simona, et al.
Publicado: (2015)

Gold Nanoparticles Disrupt the IGFBP2/mTOR/PTEN Axis to Inhibit Ovarian Cancer Growth
por: Hossen, Md. Nazir, et al.
Publicado: (2022)

Role of PTEN, PI3K, and mTOR in Triple-Negative Breast Cancer
por: Prvanović, Mirjana, et al.
Publicado: (2021)

Targeting mTOR Pathway in PTEN Deleted Newly Isolated Chordoma Cell Line
por: Pagani, Francesca, et al.
Publicado: (2023)

Effects of dacomitinib on the pharmacokinetics of poziotinib in vivo and in vitro
por: Ji, Weiping, et al.
Publicado: (2021)

The mTOR pathway genes mTOR, Rheb, Depdc5, Pten, and Tsc1 have convergent and divergent impacts on cortical neuron development and function
por: Nguyen, Lena H., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_id5g2fnr4tl835h2gtemuh61j7